Delivery Order SPE2DB24D2205-SPE2DB26FDSSK
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 29, 2025, for the supply of RINVOQ ER 45 mg tablets (28-count units) under a firm fixed-price contract valued at $15,357.41. This non-set-aside delivery order, with an ultimate completion date of September 30, 2025, represents a procurement of pharmaceutical products to support federal medical supply requirements. The order will be performed at AmerisourceBergen's corporate office location in...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 22, 2025, for the supply of RINVOQ ER 30 mg tablets (30-count units) at a ceiling value of $24,715.95. This is a firm fixed-price delivery order with no set-aside designation, reflecting a competitively awarded contract. The order is scheduled for completion by October 23, 2025, and will be fulfilled from AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 14, 2025, for the supply of RINVOQ ER 30 mg tablets (30-unit packages) valued at $34,458.64. This competitively awarded, firm fixed-price delivery order represents a non-set-aside procurement with an ultimate completion date of July 15, 2025. The award supports the agency's pharmaceutical supply chain requirements, with performance based in Conshohocken, Pennsylvania, where AmerisourceBergen's...
- The Defense Logistics Agency awarded a $23,543.70 delivery order to AmerisourceBergen Drug Corp on September 16, 2025, for the supply of RINVOQ ER 30 mg tablets (30-count units). This competitively awarded, firm fixed-price contract represents a non-set-aside procurement and is scheduled for completion by September 17, 2025. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its primary operations as a major...
- The Defense Logistics Agency awarded a competitive delivery order to AmerisourceBergen Drug Corp on September 12, 2025, for the supply of RINVOQ ER 30 mg tablets in quantities of 30 units. The contract represents a firm fixed price delivery order with a ceiling value of $38,113.45 and an ultimate completion date of September 15, 2025. This non-set-aside award reflects AmerisourceBergen's continued role as a critical pharmaceutical supplier to the federal government, with performance taking place...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 26, 2025, for the supply of RINVOQ ER 30 mg tablets (30-count units) under a firm fixed-price contract with a ceiling value of $77,613.62. This non-set-aside competitive award is a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The ultimate completion date for...
- The Defense Logistics Agency awarded a delivery order valued at $32,555.23 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on August 26, 2025, with an ultimate completion date of August 27, 2025. This competitively awarded, non-set-aside delivery order utilizes firm fixed pricing and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract vehicle with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026....
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 12, 2025, for the supply of RINVOQ ER 30 mg tablets in packages of 30 units. This competitively awarded, non-set-aside contract has a firm fixed price ceiling value of $9,334.98 with an ultimate completion date of September 15, 2025. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's...
- The Defense Logistics Agency awarded a $30,354.57 delivery order to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of RINVOQ ER 45 mg tablets (28-count units). This is a firm fixed-price delivery order with no set-aside designation, to be performed at the vendor's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of August 18, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical vendor for federal medical...
- The Defense Logistics Agency awarded a delivery order contract to AmerisourceBergen Drug Corp on July 23, 2025, for the supply of RINVOQ ER 30 mg tablets in quantities of 30 units. This is a competitively awarded, firm fixed-price delivery order with a ceiling value of $19,727.87 and an ultimate completion date of July 24, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's...
- SPE2DB24D2205Indefinite Delivery Contract
- SPE2DB24D2205-SPE2DB26FDSSKDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 23, 2025, for supply of RINVOQ ER 45 mg tablets (28-count units) with a ceiling value of $44,114.13. This competitively awarded, firm fixed-price delivery order is non-set-aside and is set to complete by October 24, 2025. The contract represents a continuation of pharmaceutical supply services to support federal medical procurement needs, with performance taking place at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. This delivery order is a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, valued at $999,999,999.00 through December 2026. As a major pharmaceutical distributor, AmerisourceBergen serves as a critical vendor for military healthcare systems and federal medical supply chains, delivering a comprehensive range of brand-name and generic medications across multiple therapeutic domains. The company's extensive portfolio of federal awards demonstrates its capability to fulfill competitive procurement requirements for the Department of Defense and related federal healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $44.1k | 10/23/25 |